A-166 is under clinical development by Sichuan Kelun Pharmaceutical and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how A-166’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

A-166 overview

A-166 is under development for the treatment of advanced, recurrent or metastatic non-small cell lung cancer, relapsed and refractory solid tumor, metastatic colorectal cancer, metastatic urothelial cancer, HER2- positive and HER2 low expressing metastatic breast cancer, recurrent or metastatic non-small cell lung cancer, colorectal cancer and metastatic gastric cancer and adenocarcinoma of gastroesophageal junction. It is administered through parenteral and intravenous route. The drug candidate is a recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to duostatin-5. It acts by targeting cells expressing human epidermal growth factor receptor 2 (HER2).

Sichuan Kelun Pharmaceutical overview

Sichuan Kelun Pharmaceutical (Kelun) a subsidiary of Sichuan Kelun Industrial Group Co Ltd, is a pharmaceutical company. The company carries out in the manufacturing and distribution of pharmaceutical products and active pharmaceutical ingredient intermediates. It offers various products including large-volume injections (infusion), small-volume injections (water injections), sterile powder injections for injection, tablets, capsules, granules, oral liquid and peritoneal dialysis products. Kelun provides products such as ampicillin capsules, norfloxacin capsules, flucloxacillin sodium and amoxicillin capsules, cefalexin capsules, quinolones, cefotaxime acid, glucoside and also clindamycin hydrochloride capsules. The company also carries out research and development of pharmaceutical products. Kelun is headquartered in Chengdu, Sichuan, China.

For a complete picture of A-166’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.